| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2ca2e4410855da087e11bf3eea8933fa |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-55 |
| filingDate |
2017-10-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_43d68a84de5bbc663bf96dcaf37b57a8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_505848398da89662c1130ad12f1c7851 |
| publicationDate |
2018-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2018071307-A1 |
| titleOfInvention |
Targeted treatment of mature t-cell lymphoma |
| abstract |
A method and medicament comprising 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2- hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo- ethyl]butanamide or a pharmaceutically acceptable salt or hydrate thereof for treating aggressive peripheral T-cell lymphoma is provided. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10555951-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11564929-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11298362-B2 |
| priorityDate |
2016-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |